Global Fatty Liver Diseases Treatment Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
USD 9.15 Billion |
 Market Size (Forecast Year) |
USD 28.00 Billion |
 CAGR |
% |
| Major Markets Players |
|
>全球脂肪肝疾病治疗市场，按类型（酒精性和非酒精性）、治疗（血液测试、影像程序、肝组织检查）、最终用户（医院、家庭护理、专科诊所、其他）、分销渠道（医院药房、网上药房、零售药房）划分 - 行业趋势和预测到 2030 年。
脂肪肝疾病治疗市场分析及规模
广泛的技术进步和常规肝功能检查在脂肪肝治疗的早期发现方面处于领先地位。脂肪肝疾病（主要是非酒精性肝病 (NAFLD)）的发病率预计在未来几年将增加约 20% 至 25%。在美国，预计有超过 1500 万人酗酒或过量饮酒，其中超过 90% 的人患有脂肪肝疾病。预测期内，整体市场正在经历巨大的增长。
Data Bridge Market Research 分析了 2023-2030 年预测期内脂肪肝疾病治疗市场的增长率。在上述预测期内，脂肪肝疾病治疗市场的预期复合年增长率趋于 15% 左右。2022 年市场价值为 91.5 亿美元，到 2030 年将增长至 280 亿美元。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、渠道分析、定价分析和监管框架。
脂肪肝疾病治疗市场范围和细分
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021（可定制为 2015 - 2020） |
|
定量单位 |
收入（单位：十亿美元）、销量（单位：台）、定价（美元） |
|
涵盖的领域 |
类型（酒精类和非酒精类）、治疗（血液检查、影像学检查、肝组织检查）、给药途径（口服、肠外）、最终用户（医院、家庭护理、专科诊所、其他）、分销渠道（医院药房、网上药房、零售药房） |
|
覆盖国家 |
北美洲的美国、加拿大和墨西哥、德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲 (MEA) 的其他地区、巴西、阿根廷和南美洲其他地区 |
|
涵盖的市场参与者 |
Pfizer Inc (U.S.), AbbVie.Inc (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Sun Pharmaceutical Industries Ltd (India), Mylan N.V. (U.S.), Novartis AG (Switzerland), Lupin (India), Cipla Inc (India), Aurobindo Pharma (India), Takeda Pharmaceutical Company Limited (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (U.S.), PT. Daewoong Pharmaceutical Company (South Korea), Cardax, Inc (Hawaii) |
|
Market Opportunities |
|
Market Definition
Fatty liver diseases are typically characterized by accumulated extra fat in the liver. The consumption of alcohol, to a large extent, build up the formation of fatty acids inside human liver cells and is thus called alcoholic liver fatty liver diseases. The prevention of fatty liver includes reducing the risk factors of obesity and adopting healthy lifestyles. Common symptoms include loss of appetite, fatigue, nose bleeds, itchy skin, weight loss, weakness, and abdominal pain, swelling of legs, abdominal swelling and breast enlargement in men.
Global Fatty Liver Diseases Treatment Market Dynamics
Drivers
- Increased Incidence of Alcohol Abuse Cases
The increasing prevalence of people with an overdose of alcohol worldwide is majorly responsible for boosting the growth of the global fatty liver diseases treatment market. As per the records of the 2019 National Survey on Drug Use and Health (NSDUH), 85.6 % of people ages 18 and older stated that they drank alcohol at some point in their lifetime. Thus, it boosts the market growth.
- Growth in Cardiovascular Diseases
As per the records of the WHO, about 60% - 85% of the population have adopted a sedentary life. According to CDC, roughly 31 million adults aged over 50 years live a sedentary life, and only 1 out of 4 U.S. adults meet the appropriate need of physical activity. This helps in the market growth.
Opportunities
- Rising R&D Activities by Several Organizations
The growing research and development activities for the treatment of chronic liver diseases is projected to drive the market growth during the forecast period. For instance, in January 2022, Madrigal Pharmaceuticals, Inc. announced positive top line clinical data from the placebo-controlled, double-blind portion of its phase 3 MAESTRO-NAFLD (non-alcoholic fatty liver disease) safety study of resmetirom. Thus, the market is expected to drive in the forecast period.
- Increasing Demand for Hospitals
The presence of a large number of hospitals in the U.S., along with a well-developed healthcare infrastructure, is another factor contributing to market growth. For instance, as per the American Hospital Association, there were around 6,090 community hospitals, 208 federal government hospitals, and 625 nonfederal psychiatric hospitals in the U.S. Major increase in the number of hospitals and hospital admissions for fatty liver diseases treatment is boosting the market growth.
Restraints/Challenges
- Lack of Drug Approvals
授权机构对药物的批准极其不足，阻碍了市场的增长。目前还没有 FDA 批准的药物用于治疗非酒精性脂肪肝病 (NAFLD) 和 NASH。此外，器官移植和肝切除等替代治疗程序的可用性预计也会限制市场的增长。
- 成本高
与这些药物相关的巨额支出阻碍了市场的增长。诊断程序（包括成像程序和肝组织检查）阻碍了市场的增长。
本脂肪肝疾病治疗市场报告详细介绍了最新发展、贸易法规、进出口分析、生产分析、价值链优化、市场份额、国内和本地市场参与者的影响，分析了新兴收入领域的机会、市场法规的变化、战略市场增长分析、市场规模、类别市场增长、应用领域和主导地位、产品批准、产品发布、地域扩展、市场技术创新。如需了解有关脂肪肝疾病治疗市场的更多信息，请联系 Data Bridge Market Research 获取分析师简报，我们的团队将帮助您做出明智的市场决策，实现市场增长。
全球脂肪肝疾病治疗市场范围
脂肪肝疾病治疗市场根据类型、治疗、分销渠道和最终用户进行细分。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。
类型
- 酒精
- 非酒精性
治疗
- 验血
- 影像学检查
- 肝组织检查
最终用户
- 医院
- 家庭护理
- 专科诊所
- 其他的
分销渠道
- 医院药房
- 网上药店
- 零售药店
脂肪肝疾病治疗市场区域分析/见解
对脂肪肝疾病治疗市场进行了分析，并按类型、治疗、分销渠道和最终用户提供了市场规模洞察和趋势。
脂肪肝疾病治疗市场报告涉及的主要国家 有：北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区（APAC）的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区（APAC）的其他地区、中东和非洲（MEA）的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。
由于新研究和开发的增加，欧洲脂肪肝疾病治疗市场在整个预测期内增长最快。
北美占据市场主导地位，因为该产品的主要制造商数量众多，且研发活动不断增加。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。此外，在提供国家数据预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈竞争或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。
竞争格局和全球脂肪肝疾病治疗市场份额分析
脂肪肝疾病治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对脂肪肝疾病治疗市场的关注有关。
脂肪肝疾病治疗市场的主要参与者包括：
- 辉瑞公司 (美国)
- Abbvie,Inc（美国）
- Endo International plc（爱尔兰）
- 梯瓦制药工业有限公司 (以色列)
- Mylan NV（美国）
- 诺华公司（瑞士）
- 鲁冰花（印度）
- Cipla Inc（印度）
- Aurobindo Pharma（印度）
- 武田药品工业株式会社 (日本)
- F. Hoffmann-La Roche Ltd（瑞士）
- 雅培（美国）
- PT. Daewoong 制药公司 (韩国)
- Cardax, Inc（夏威夷）
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
